Tumor angiogenesis and anti-angiogenic therapies
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Angiogenesis, the development and growth of blood vessels, is a major topic of research which began in 1971 with Folkman's original hypothesis. Different mechanisms of blood vessel growth are sprouting and intussusceptive angiogenesis, vascular mimicry, and blood vessel cooption. Dis-regulated angiogenesis may result in numerous angiogenic diseases and is responsible for solid tumor growth and metastasis. Vascular endothelial cells are generally dormant in adult but in pathological conditions when tumors reach a size of about 0.2-2.0 mm in diameter, they become hypoxic and hindered in tumor growth in the lack of angiogenesis. During angiogenic switch pro-angiogenic factors predominate and result in angiogenesis and tumor progression. Angiogenesis switch leads to the increased production of vascular endothelial growth factor (VEGF) following up-regulation of the hypoxia-inducible transcription factor. The VEGF family comprises from VEGF (VEGF-A), VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). The VEGF family of receptors consists of three protein-tyrosine kinases. Now, the most conventional approach for controlling tumor angiogenesis is blockade of the vascular endothelial growth factor (VEGF) pathway. The results of preclinical studies, substantial therapeutic effects of VEGF blockers have been stated in various types of human cancers, even in progressive or recurrent cancer cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 4×
“Pazopanib (orphan drug) is a new VEGFR, PDGFR and KIT inhibitor which has shown activity in RCC and ovarian cancer in Phase III clinical trial with potential synergy between pazopanib and lapatinib [43].”
InfluentialBasic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“Anti-angiogenic compounds in use or in development for the treatment of cancer, inhibit VEGFR, PDGFR, KIT, colony-stimulating factor 1 receptor (CSF-1R), FMS-like tyrosine kinase 3 receptor (FLT3), RAF kinase and glial cell line-derived neurotrophic factor (RET), expressed by tumor cells [40,43].”
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653 · cited 1×
“During local destruction of endothelial basement membrane of the wall of preexisting blood vessel, endothelial cells, pericytes, and vascular smooth muscle cells detach and migrate towards angiogenic stimuli [1].”
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Although significant therapeutic effect of VEGF blockers, at the end of 2010, FDA announced that bevacizumab is neither safe, nor effective and the FDA decided to remove market approval drug [8,39].”
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“Activation of the angiogenic switch is done via the secretion of growth factors and cytokines, oncogene activation, inactivation of tumor-suppressor genes and particularly via tumor-associated hypoxia [49].”
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536 · cited 2×
“E, and placenta growth factor (PlGF-1 and -2) [38].”
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685 · cited 1×
“…(Nexavar) is a multi-targeted inhibitor of VEGFR, PDGFR, KIT and RAF kinases, in combination with paclitaxel was approved in FDA for patients with hepatocellular carcinoma (HCC), breast cancer and advanced RCC. RAF kinases are regulators of tumor cell proliferation and angiogenesis [16,28].”
Cited by
Xie, C., Wan, X., Quan, H., Zheng, M., Fu, L., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 348
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases
Fallah, A., Sadeghinia, A., Kahroba, H., Samadi, A., Heidari, H. R., Bradaran, B., Zeinali, S., & Molavi, O. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.022 · Cited by 259
Cancer combination therapies by angiogenesis inhibitors; a comprehensive review
Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197
Huang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Self-citation
Metadata
- Authors
- Shahneh, F. Z., Baradaran, B., Zamani, F., & Aghebati-Maleki, L.
- Venue
- Human Antibodies
- Publisher
- SAGE Publications
- Published
- 2013-11-18
- Volume
- 22
- Issue
- 1-2
- Pages
- 15-19
- ISSN
- 0956-960X (ISSN-L)
- 1875-869X
- 1093-2607
- OpenAlex
- W1903631329
- Cited by
- 80
- References
- 8
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor angiogenesis and anti-angiogenic therapies. https://app.cochat.ai/papers/10.3233/hab-130267
- The paper
- Shahneh, F. Z., Baradaran, B., Zamani, F., & Aghebati-Maleki, L. (2013). Tumor angiogenesis and anti-angiogenic therapies. Human Antibodies. https://doi.org/10.3233/hab-130267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.